Homozygous Novel Variants in the Glycine Decarboxylase Gene Associated with Nonketotic Hyperglycinemia in a Distinct Population

Abstract

Glycine encephalopathy (GE), also known as nonketotic hyperglycinemia (NKH) is an autosomal recessive disorder due to a primary defect in the glycine cleavage enzyme system. It is characterized by elevated levels of glycine in the plasma and cerebrospinal fluid (CSF) and increased CSF to plasma glycine ratio.

Mutations in three genes of the mitochondrial glycine cleavage system have been found to cause NKH. Most patients have a mutation in the GLDC.

In this report, we present five new patients from Middle Eastern families with NKH. They were all born to consanguineous parents and two of them have family history of similarly affected sibling(s). All patients presented with neonatal encephalopathy associated with seizures. Their diagnoses were suspected clinically and confirmed biochemically.

DNA sequence analysis of the five patients revealed five different pathogenic or likely pathogenic variants in the GLDC. Three were missense variants (c.2675C > T; p.Ala892Val), (c.2512A > G; p.Asn838Asp), and (c.2943A > C; p.Lys981Asn); one was an intronic missense variant (c.1402–2A > T) leading to an exonic deletion, and one was a deletion of 42 amino acids (c.1927-?_2052 + ?del.) All variants were novel and homozygous. The pathogenicity of these variants was determined according to the American College of Medical Genetics (ACMG) variant classification and in silico analysis. Another novel homozygous variant (c.1384C > G; p.Leu462Val) was detected, which was classified as likely benign.

The novel variants identified in the GLDC in these patients underlie the pathogenesis of NKH, specifically for the Middle Eastern population. This expands the mutation spectrum of NKH to include a distinct ethnic population that has not been studied before.

Keywords

glycine encephalopathy - nonketotic hyperglycinemia - GLDC variants - ethnic population - Middle East population

Publication History

Received: 03 December 2020

Accepted: 21 March 2021

Article published online:
11 June 2021

• References

• 1 Van Hove JL, Curtis Coughlin II, Swanson M, Hennermann JB. Nonketotic hyperglycinemia. In: GeneReviews®[internet]. University of Washington; Seattle: 2019
• 2 Isobe M, Koyata H, Sakakibara T, Momoi-Isobe K, Hiraga K. Assignment of the true and processed genes for human glycine decarboxylase to 9p23-24 and 4q12. Biochem Biophys Res Commun 1994; 203 (03) 1483-1487
• 3 Nanao K, Okamura-Ikeda K, Motokawa Y. et al. Identification of the mutations in the T-protein gene causing typical and atypical nonketotic hyperglycinemia. Hum Genet 1994; 93 (06) 655-658
• 4 Kure S, Kojima K, Kudo T. et al. Chromosomal localization, structure, single-nucleotide polymorphisms, and expression of the human H-protein gene of the glycine cleavage system (GCSH), a candidate gene for nonketotic hyperglycinemia. J Hum Genet 2001; 46 (07) 378-384
• 5 Coughlin II CR, Swanson MA, Kronquist K. et al. The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT. Genet Med 2017; 19 (01) 104-111
• 6 Takayanagi M, Kure S, Sakata Y. et al. Human glycine decarboxylase gene (GLDC) and its highly conserved processed pseudogene (psiGLDC): their structure and expression, and the identification of a large deletion in a family with nonketotic hyperglycinemia. Hum Genet 2000; 106 (03) 298-305
• 7 The human gene mutation database (HGMD) at the institute of medical genetics in cardiff. Accessed August, 2020 at: http://Www.hgmd.cf.ac.uk/ac/gene.php?geneZGLDC
• 8 Tada K, Kure S. Nonketotic hyperglycinemia: pathophysiological studies. Proc Jpn Acad, Ser B, Phys Biol Sci 2005; 81 (10) 411-417
• 9 Chiu CF, Lin JL, Lin JJ, Tseng MH, Lo FS, Chiang MC. Nonketotic hyperglycinemia of infants in taiwan. Pediatr Neonatol 2016; 57 (05) 420-426
• 10 Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000; 105 (01) e10
• 11 Al Riyami S, Al Maney M, Joshi SN, Bayoumi R. Detection of inborn errors of metabolism using tandem mass spectrometry among high-risk omani patients. Oman Med J 2012; 27 (06) 482-485
• 12 Mohammad SA, Abdelkhalek HS. Nonketotic hyperglycinemia: spectrum of imaging findings with emphasis on diffusion-weighted imaging. Neuroradiology 2017; 59 (11) 1155-1163
• 13 Al-Shamsi A, Hertecant JL, Al-Hamad S, Souid AK, Al-Jasmi F. Mutation spectrum and birth prevalence of inborn errors of metabolism among emiratis: a study from tawam hospital metabolic center, united arab emirates. Sultan Qaboos Univ Med J 2014; 14 (01) e42-e49
• 14 Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983-2008. Ann Saudi Med 2010; 30 (04) 271-277
• 15 Roy D, Al-Asmari A, Ghazal YK, Al-Oqiel S. Nonketotic hyperglycinemia in suleimaniah children's hospital, Riyadh, Saudi Arabia. Ann Saudi Med 2004; 24 (05) 378-381
• 16 Nasrallah F, Hadj-Taieb S, Chehida AB. et al. Nonketotic hyperglycinemia in tunisia. report upon a series of 69 patients. Neuropediatrics 2020; 51 (05) 349-353
• 17 Liu S, Wang Z, Liang J. et al. Two novel mutations in the glycine decarboxylase gene in a boy with classic nonketotic hyperglycinemia: case report. Arch Argent Pediatr 2017; 115 (04) e225-e229
• 18 Iqbal M, Prasad M, Mordekar SR. Nonketotic hyperglycinemia case series. J Pediatr Neurosci 2015; 10 (04) 355-358
• 19 Stence NV, Fenton LZ, Levek C. et al. Brain imaging in classic nonketotic hyperglycinemia: quantitative analysis and relation to phenotype. J Inherit Metab Dis 2019; 42 (03) 438-450
• 20 Poothrikovil RP, Al Thihli K, Al Futaisi A, Al Murshidi F. Nonketotic hyperglycinemia: two case reports and review. Neurodiagn J 2019; 59 (03) 142-151
• 21 Swanson MA, Coughlin Jr CR, Van Hove JL. Corrigendum: Swanson MA, Coughlin CR Jr, Scharer GH, et al: Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia. Ann Neurol 2015;78:606-618. Ann Neurol 2016; 79 (03) 505
• 22 Hennermann JB, Berger JM, Grieben U, Scharer G, Van Hove JL. Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Dis 2012; 35 (02) 253-261
• 23 Kure S, Takayanagi M, Narisawa K, Tada K, Leisti J. Identification of a common mutation in Finnish patients with nonketotic hyperglycinemia. J Clin Invest 1992; 90 (01) 160-164
• 24 Toone JR, Applegarth DA, Coulter-Mackie MB, James ER. Recurrent mutations in P- and T-proteins of the glycine cleavage complex and a novel T-protein mutation (N145I): a strategy for the molecular investigation of patients with nonketotic hyperglycinemia (NKH). Mol Genet Metab 2001; 72 (04) 322-325
• 25 Kure S, Kato K, Dinopoulos A. et al. Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia. Hum Mutat 2006; 27 (04) 343-352
• 26 Boneh A, Korman SH, Sato K. et al. A single nucleotide substitution that abolishes the initiator methionine codon of the GLDC gene is prevalent among patients with glycine encephalopathy in Jerusalem. J Hum Genet 2005; 50 (05) 230-234
• 27 Korman SH, Boneh A, Ichinohe A. et al. Persistent NKH with transient or absent symptoms and a homozygous GLDC mutation. Ann Neurol 2004; 56 (01) 139-143
• 28 Toone JR, Applegarth DA, Coulter-Mackie MB, James ER. Identification of the first reported splice site mutation (IVS7-1G-->A) in the aminomethyltransferase (T-protein) gene (AMT) of the glycine cleavage complex in 3 unrelated families with nonketotic hyperglycinemia. Hum Mutat 2001; 17 (01) 76
• 29 Sellner L, Edkins E, Greed L, Lewis B. Detection of mutations in the glycine decarboxylase gene in patients with nonketotic hyperglycinaemia. Mol Genet Metab 2005; 84 (02) 167-171
• 30 Flusser H, Korman SH, Sato K, Matsubara Y, Galil A, Kure S. Mild glycine encephalopathy (NKH) in a large kindred due to a silent exonic GLDC splice mutation. Neurology 2005; 64 (08) 1426-1430